June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
3-D Computer-Automated Threshold Amsler Grid to Quantify Retinal Deficits Before and After Standard Treatment of Wet Age-related Macular Degeneration
Author Affiliations & Notes
  • Kristie Lin
    Retina Institute of California, Arcadia, CA
  • Wolfgang Fink
    Physics, Mathematics and Astronomy, California Institute of Technology, Pasadena, CA
    Biomedical Engineering, University of Arizona, Tuscon, AZ
  • Sami Kamjoo
    Retina Institute of California, Arcadia, CA
  • Michael Davis
    Retina Institute of California, Arcadia, CA
  • Tom Chang
    Retina Institute of California, Arcadia, CA
  • Footnotes
    Commercial Relationships Kristie Lin, Janssen Pharmaceutical Companies (C), Thrombogenics (C), Sequenom (C); Wolfgang Fink, University of Arizona (P), California Institute of Technology (P); Sami Kamjoo, None; Michael Davis, Sequenom (C), Johnson and Johnson Research and Development (C), Synergetics (C), Allergan (C), Citi Financial Group (C); Tom Chang, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4642. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kristie Lin, Wolfgang Fink, Sami Kamjoo, Michael Davis, Tom Chang; 3-D Computer-Automated Threshold Amsler Grid to Quantify Retinal Deficits Before and After Standard Treatment of Wet Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4642.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To characterize and quantify disease activity and response to treatment of wet Age-related Macular Degeneration (AMD) with standard intravitreal anti-VEGF agents using 3-D Computer-Automated Threshold Amsler Grid (3D-CTAG) as a functional assessment of macular function over time.

 
Methods
 

10 eyes in 10 patients with wet AMD underwent quantification of central field abnormalities with 3D-CTAG (Fink & Sadun, JBO 2004) before and one week after treatment with standard intravitreal anti-VEGF agents including bevacizumab (Avastin, Genentech), ranibizumab (Lucentis, Genentech), and aflibercept (Eyelea, Regeneron). Quantitative analysis of 3D visual field abnormalities included: Lost Area Grade (LAG = scotoma area ratio as a function of contrast sensitivity), Preserved Area Grade (PAG = intact visual field area ratio as a function of contrast sensitivity), and Hill-of-Vision Volume Loss (HVL = ratio of not seen vs. total number of Amsler grid points).

 
Results
 

Wet AMD patients exhibited a central defect at low vs. a larger central defect at higher contrast sensitivity levels. We demonstrated the quantification and improvement of macular structure and function using 3D-CTAG before and after standard treatment of wet AMD: LAG, PAG, and HVL indices showed marked improvement following treatment, which correlated with regression of the choroidal neovascular membrane complex after use of standard anti-VEGF agents. Overall, 3D-CTAG provided easy clinical access to measuring and assessing the functional health of the retina in vivo to quantify change over time.

 
Conclusions
 

3D-CTAG is a direct, non-invasive, and easy-to-use functional retinal imaging technology. It allows characterization and quantification of longitudinal changes in macular function before and after treatment of patients with wet AMD. 3D-CTAG may prove useful as a screening tool in wet AMD and other central macular diseases like geographic atrophy due to dry AMD. As newer therapeutics are developed, the distinctive and quantitative measurements offered by 3D-CTAG may become an increasingly important marker to characterize AMD, monitor disease severity, and provide quantitative outcome measures of therapy. Objective indices (e.g., LAG, PAG, HVL) delivered by 3D-CTAG may serve as useful adjunctive measures in clinical trials guided by functional outcomes.

 
Keywords: 550 imaging/image analysis: clinical • 412 age-related macular degeneration • 585 macula/fovea  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×